6623-81-0Relevant articles and documents
Preparation method of 2-chloro-5-methoxypyrimidine
-
Paragraph 0014-0017, (2019/10/23)
The invention relates to the field of compound preparation methods, and in particular relates to a preparation method of 2-chloro-5-methoxypyrimidine, which is prepared by taking methyl methoxyacetateas a raw material. The product prepared by the preparation method has high purity, the catalyst and the solvent can be recycled, the reaction is mild, the control is easy, and the method is suitablefor industrial production.
COMPOUNDS
-
Page/Page column 26, (2011/12/04)
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH; Q is NR6 or O; A1 and A2 are independently hydrogen or C1-6 alkyl or may together form a carbonyl group; R1 and R2 are independently hydrogen, halogen, CF3, CN, OR7, OR8, NR8R9, NR8COR10, NR8S02R10, S02NR8R9, SO2R10 or C1-6 alkyl optionally and independently substituted by one or more of hydroxyl, C1-6 alkoxy, halogen or NR8 R9; R 3 is hydrogen, halogen, CF3 or OR 7; R4 is hydrogen, halogen, CF3, OR8, NR8R9, NR8COR10, NR8S02R10 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR 8 R 9; or when R3 and R4 are positioned ortho and taken together form -0(CH2)mO-, where m is 1-3; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR8 R9; R6 is hydrogen or C1-6 alkyl; R7 is hydrogen or C1-6 alkyl optionally substituted by OR8 or NR8R9; R8 is hydrogen, C1-6 alkyl, optionally substituted by hydroxyl or C1-6 alkoxy or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR7, NR8R9 or OCF3; or the groups R8 and R9 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR7, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C1-6 alkoxy; or the groups R8 and R9 when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C1-6 alkoxy; and R10 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR7; and n is 1 or 2. The use of the compounds in treating amyloid disease is also disclosed.
Experimental measurement and correlation of the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane at temperatures between (295 and 320) K
Liu, Yong-Jie,Luo, Ting-Liang,Yao, Xin-Ding,Mao, Zhi-Bo,Liu, Guo-Ji
body text, p. 1402 - 1404 (2010/09/04)
The solid-liquid equilibrium of 2,4-dichloro-5-methoxypyrimidine was first determined in this article. Using a laser monitoring observation technique, the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane have been determined experimentally from (295.60 to 316.39, 302.37 to 316.95, 299.44 to 316.61, 297.35 to 311.37, 298.60 to 312.15, and 298.10 to 320.08) K, respectively. The results are correlated with λ-h equation and Apelblat equation. The calculated results show that the correlation of the Apelblat model for six measured systems has less deviation than that of the λ-h equation.